Akira Kazama

Dr. Akira Kazama

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2023 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
WAWorapat Attawettayanon
Worapat Attawettayanon
YYYosuke Yasuda
Yosuke Yasuda
JZJj H. Zhang
Jj H. Zhang
NRNityam Rathi
Nityam Rathi
CMCarlos Munoz-Lopez
Carlos Munoz-Lopez
SCSteven C. Campbell
Steven C. Campbell

14 February 2024 in BJU International
Verified
Journal Article
Closed access
AKAkira Kazama
Akira Kazama
WAWorapat Attawettayanon
Worapat Attawettayanon
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
NRNityam Rathi
Nityam Rathi
KLKieran Lewis
Kieran Lewis
SCSteven C. Campbell
Steven C. Campbell

19 March 2025 in BJUI Compass
Verified
Journal Article
Open access
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
KLKieran Lewis
Kieran Lewis
NRNityam Rathi
Nityam Rathi
EMEran Maina
Eran Maina
AKAkira Kazama
Akira Kazama
SCSteven C. Campbell
Steven C. Campbell
Background and Objectives: In most patients, the renal parenchymal volumes in each kidney directly correlate with function and can be used as a proxy to determine split renal function (SRF). This simple principle forms the basis for parenchymal volume analysis (PVA) with semiautomated software, which can be leveraged to predict SRF and new‐baseline glomerular filtration rate (NBGFR) following nephrectomy. PVA was originally used to evaluate renal transplantation donors and has replaced nuclear renal scans (NRS) in this domain. PVA has subsequently been explored for the management of patients with kidney cancer for whom difficult decisions about radical versus partial nephrectomy can be influenced by accurate prediction of NBGFR. Our objective is to present a comprehensive review of the applications of PVA in urology including their clinical and research implications.Methods: Key articles utilizing renal PVA to improve clinical care and facilitate urologic research were reviewed with special emphasis on take‐home points of clinical relevance and their contributions to progress in the field.Results: There have been considerable advances in renal PVA over the past 15 years, which is now established as a reference standard for the prediction of functional outcomes after renal surgery. PVA provides improved accuracy when compared to NRS‐based estimates or non‐SRF‐based algorithms. PVA can be performed in minutes using routine preoperative cross‐sectional imaging and can be readily applied at the point of care. Additionally, PVA has important research applications, enabling the precise study of the determinants of functional recovery after partial nephrectomy, which can affect surgical approaches to this procedure.Conclusions: Despite the wide availability of PVA, primarily for use in renal transplantation, it has not been widely implemented for other urologic purposes at most centres. Our hope is that this narrative review will increase PVA utilization in urology and facilitate further progress in the field.

27 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAkira Kazama
Akira Kazama
VBVladimir Bilim
Vladimir Bilim
MTMasayuki Tasaki
Masayuki Tasaki
TATsutomu Anraku
Tsutomu Anraku
HKHiroo Kuroki
Hiroo Kuroki
YTYoshihiko Tomita
Yoshihiko Tomita
Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic renal cell carcinoma (mRCC). Although many studies have reported biomarkers as predicting the efficacy of ICI in mRCC, they remain controversial and have challenges to apply in real-world practice. We evaluated prognostic significance of multiple molecules associated with tumor immunity in patients treated with ICI. The molecules were detected in tumor tissues by immunohistochemical staining. We identified CD8-positive T cells and CD68-positive macrophages infiltrating into the tumor tissue as significant favorable prognostic factors for ICI treatment. Conversely, high expression of CD4-positive T cells was associated with poor response to ICI. Furthermore, we demonstrated that scoring for the expression status of these three molecules provides a remarkably accurate biomarker in patients with mRCC. Even the classical approach of immunohistochemistry could predict the outcome of ICI treatment by assessing the combined status of tumor-infiltrating immune cells.

28 November 2024 in BJU International
Verified
Journal Article
Closed access
AKAkira Kazama
Akira Kazama
CMCarlos Munoz‐Lopez
Carlos Munoz‐Lopez
KLKieran Lewis
Kieran Lewis
WAWorapat Attawettayanon
Worapat Attawettayanon
NRNityam Rathi
Nityam Rathi
SCSteven C. Campbell
Steven C. Campbell

26 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KFKazutoshi Fujita
Kazutoshi Fujita
Go KimuraGo Kimura
Go Kimura
TTToyonori Tsuzuki
Toyonori Tsuzuki
TKTaigo Kato
Taigo Kato
EBEri Banno
Eri Banno
HUHirotsugu Uemura
Hirotsugu Uemura
Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis.